来源：新甘肃客户端 编辑：王学香责编：朱旺 校审：祁晴 面对养老与医疗服务的双重需求，金昌市创新构建了协议管理、居家签约、社区服务、内设机构、共融共建五种模式，系统推广"社区 +居家+机构"三位一体、"医疗+康复+照护+居家"四位一体等综合服务，实现了城乡社区"15分钟养老服务圈"的全覆盖。 在医疗服务支撑方面，金昌市持续加强老年健康服务能力建设。全市6家二级以上综合医院已全部设立老年病科，组建的110个家庭医生 团队，为老年人提供包括健康管理、上门巡诊、转诊协调在内的连续性服务，努力做到"慢病有管理、小病能处理、大病易转诊"，老年 人健康管理率超过80%。同时，中医药在医养结合中的作用得到充分发挥，基层医疗卫生机构普遍设立中医科和中药房，广泛推广适宜 技术与食疗保健方法。作为全国安宁疗护试点地区，金昌已初步建立起以市属医院为核心的服务网络，相关工作获得省级认可。 人才队伍建设与信息化应用为服务体系提供了坚实保障。"十四五"期间，金昌市通过实施专项培训计划，累计培训各类养老人才超过 3500人次，本地职业院校开设相关专业，年均培养专业人才200余人。在智慧养老方面，依托全民健康信息平台，建立了统一的医养结合 ...

Core Viewpoint - Aier Eye Hospital Group Co., Ltd. is acquiring partial equity stakes in 39 medical institutions to enhance its market competitiveness and improve its tiered medical service system [1]. Group 1: Stock Performance - As of December 25, 2025, Aier Eye's stock closed at 11.14 yuan, up 0.18% from the previous trading day, with a total market capitalization of 103.885 billion yuan [1]. - The stock opened at 11.15 yuan, reached a high of 11.17 yuan, and a low of 11.05 yuan, with a trading volume of 4.32 billion yuan and a turnover rate of 0.49% [1]. Group 2: Acquisition Details - The company plans to use its own funds amounting to 963.0228 million yuan to acquire partial equity in 39 medical institutions [1]. - This acquisition does not constitute a related party transaction or a major asset restructuring, and it does not require approval from the shareholders' meeting [1]. - Post-acquisition, the company will hold varying equity stakes in the targeted hospitals, which are primarily located in city and county-level areas, aiding in the implementation of tiered diagnosis and treatment policies and promoting the distribution of quality medical resources [1].

南财智讯12月25日电，何氏眼科公告，公司董事会近日收到董事、董事会秘书周晋峰先生提交的书面辞 职报告。周晋峰先生因个人原因申请辞去公司董事、董事会秘书职务，辞职后不再担任公司任何职务。 根据相关规定，其辞职报告自送达董事会之日起生效。截至公告披露日，周晋峰先生未持有公司股份， 亦不存在应当履行而未履行的承诺事项。为保证相关工作顺利开展，在聘任新的董事会秘书之前，暂由 公司总经理何星儒先生代为履行董事会秘书职责。公司董事会已提名何星儒先生为第三届董事会非独立 董事候选人，该议案尚需提交股东大会审议。 ...

Market Overview - The medical services sector increased by 1.03% on December 25, with Baihua Medicine leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Gainers in Medical Services - Baihua Medicine (600721) closed at 11.56, up 6.54% with a trading volume of 396,400 shares and a transaction value of 449 million [1] - Zhaoyan New Drug (603127) closed at 37.38, up 4.24% with a trading volume of 254,500 shares and a transaction value of 266.56 million [1] - Aoyang Health (002172) closed at 4.18, up 3.98% with a trading volume of 330,500 shares and a transaction value of 137 million [1] Top Losers in Medical Services - Yinos (688710) closed at 44.60, down 1.87% with a trading volume of 16,000 shares and a transaction value of 71.19 million [2] - Baiao Saitou (688796) closed at 51.80, down 1.52% with a trading volume of 35,500 shares and a transaction value of 184 million [2] - Yangguang Nuohuo (688621) closed at 68.01, down 1.29% with a trading volume of 32,700 shares and a transaction value of 223 million [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 148 million from institutional investors and 126 million from retail investors, while retail investors saw a net inflow of 275 million [2] - Zhaoyan New Drug had a net inflow of 164 million from institutional investors, while Baihua Medicine saw a net inflow of 45.83 million [3] - The overall capital flow indicates a mixed sentiment among different investor categories within the medical services sector [3]

Group 1 - The core point of the article highlights the recent performance of Yueshen Health, with a stock price increase of 5.33% to 4.94 CNY per share, a trading volume of 140 million CNY, and a total market capitalization of 4.543 billion CNY [1] - Yueshen Health, established on June 8, 1993, and listed on August 23, 2007, operates in high-end ceramic tiles and ecological functional building materials, focusing on the "Yueshen Health" brand in healthcare and elderly services [1] - The revenue composition of Yueshen Health includes: 35.96% from marble tiles, 31.86% from antique tiles, 11.19% from health services, 8.71% from warehouse leasing, 6.71% from ceramic tiles, 5.09% from glass-ceramic tiles, and 0.48% from other tile products [1] Group 2 - The top circulating shareholder of Yueshen Health is the Guotai Fund, which holds 1.9629 million shares of the Guotai CSI All Index Building Materials ETF, accounting for 0.21% of the circulating shares [2] - The Guotai CSI All Index Building Materials ETF, established on June 9, 2021, has a current size of 1.102 billion CNY and has achieved a year-to-date return of 12.31% [2] - The fund manager, Huang Yue, has a tenure of 4 years and 325 days, with the fund's total asset size at 35.78 billion CNY, achieving a best return of 44.94% and a worst return of -60.42% during the tenure [3]

（来源：廊坊日报） 转自：廊坊日报 本报讯（记者 马颖劼）为弘扬尊师重教的优良传统，表达对退休教师的关怀与敬意，近日，廊坊一中 携手廊坊健康管理医院组织开展了离退休教师健康义诊活动，为曾耕耘讲台数十载的教育工作者们送上 了一份健康厚礼。 为精准回应离退休教师"常见病防治、慢性病管理、康复保健"等健康需求，学校工会与廊坊健康管理医 院提前精心筹备，组建了一支由内科、放射科、超声科资深专家组成的多学科爱心医疗团队走进家属院 社区，将优质服务送到了家门口。 活动现场，专家们俯身为离退休教师问诊、听诊、叩诊，翻看既往病历，对高血压、糖尿病、骨质疏松 等常见慢性病调养问题进行细致解答，还耐心宣传常见疾病的预防和保健知识，根据每位老师的身体状 况给予个性化的健康建议。 廊坊一中将持续关注退休教师的健康需求，不断丰富活动形式和内容，提升服务质量，为离退休教师的 健康保驾护航。 ...

Investment Rating - The report indicates a positive outlook for the healthcare sector, particularly the biopharmaceutical industry, which is expected to continue its recovery into 2026 [4][5]. Core Insights - The biopharmaceutical sector has shown significant recovery, with a 12% increase this year, narrowing the gap with the S&P 500 index, which has risen by 14% [2][3]. - Key drivers for this recovery include improved policy clarity regarding drug pricing and a resurgence in investor confidence in innovation across various therapeutic areas, particularly in obesity and cardiovascular diseases [3][4]. - The report highlights that major biopharmaceutical companies are experiencing upward revisions in sales expectations for the first time in years, indicating a positive shift in market sentiment [3][5]. Summary by Sections Biopharmaceutical Sector - The biopharmaceutical industry is expected to see sustained recovery, driven by clearer drug pricing policies and the initiation of new product cycles [4][5]. - Major companies like Amgen and Regeneron are anticipated to have upward performance potential, while BioGen is expected to improve due to stable earnings and catalysts [8]. - The report emphasizes the importance of mergers and acquisitions as a significant theme, with the industry likely entering a consolidation phase [8][12]. Medical Technology - The medical technology sector is projected to experience organic growth slowdown, but there are numerous product catalysts that could drive performance [25][26]. - Companies like Edwards and Abbott are highlighted as having significant growth potential, with expectations of increased merger activity [25][26]. Healthcare Services - The report discusses the managed care sector, indicating that it is currently in a typical underwriting cycle, with a potential recovery in Medicare Advantage plans expected in 2026 [32][33]. - The report suggests a cautious outlook for managed Medicaid plans and exchanges, with specific companies receiving varied ratings based on their performance and market conditions [33]. Investment Opportunities - The report identifies several stocks as potential investment opportunities for 2026, including UnitedHealth Group (UNH), Cytokinetics, and Abbott, among others [44].

Core Viewpoint - The successful launch of the "CyberKnife" at Lianyungang First People's Hospital marks a significant advancement in high-precision and intelligent radiotherapy for cancer treatment, aligning with China's health strategy and enhancing regional oncology capabilities [2][3]. Group 1: Event Overview - The second academic conference of the Jiangsu Immunology Society's Nutrition and Immunity Committee was held in Lianyungang on December 20, featuring the inauguration of the "CyberKnife" radiotherapy system [2]. - Experts from various medical institutions attended the conference, including leaders from the Beijing-Japan Friendship Hospital and Jiangsu Provincial Cancer Hospital, who participated in the unveiling ceremony of the "CyberKnife" [2]. Group 2: Technology and Benefits - The "CyberKnife" is a high-precision radiotherapy system that miniaturizes a linear accelerator and mounts it on a robotic arm, offering advantages such as omnidirectional focusing, multi-angle incidence, and real-time dynamic tracking of tumor targets [3]. - The system is designed to provide non-invasive, precise, efficient, and safe treatment options for patients with tumors in multiple body parts, especially for those who cannot tolerate surgery or have poor outcomes with traditional radiotherapy [3]. Group 3: Strategic Implications - The launch of the "CyberKnife" is part of the hospital's efforts to respond to the "Healthy China" strategy and aims to enhance the development of oncology disciplines, clinical research, and technological innovation [3]. - A professional team will be established to maximize the effectiveness of the "CyberKnife," aiming to benefit more cancer patients [3].

（来源：邯郸日报） 日前，邯郸市第四医院组织神内二科、中医科、消化内科、儿童康复中心、急诊科、B超室的多位业务骨干组成义诊团队，走进峰峰镇人民社 区开展巡回诊疗活动。 韩英杰 摄 转自：邯郸日报 ...

Core Viewpoint - The article emphasizes the increasing pressure on basic medical insurance in China, highlighting the need for a multi-tiered healthcare financing system where commercial insurance can play a crucial role in addressing funding gaps and meeting rising healthcare demands [2][3]. Summary by Sections Current State of Medical Insurance - The medical insurance fund is under significant pressure, with a projected total expenditure of 5.8 trillion yuan in 2024, where medical insurance accounts for 51%, commercial insurance for 7%, and out-of-pocket expenses for 42% [4][6]. - The income growth of medical insurance has been declining, with a year-on-year increase of only 3.9% in 2024, which is lower than the growth rate of expenditures [6][11]. Challenges in Medical Insurance - The income side faces challenges due to rising retirement rates, local fiscal pressures, and declining consumer willingness to spend, impacting the basic medical insurance revenue [11]. - On the expenditure side, the aging population and increasing number of retirees are expected to heighten the pressure on medical insurance payments [11][17]. Reform and Cost Control Measures - The article discusses the nationwide rollout of cost control measures inspired by the Sanming model, which has successfully reduced medical costs while maintaining service quality [11][12]. - Significant measures include the promotion of centralized drug procurement and adjustments to medical service pricing, which have led to a noticeable decrease in overall medical expenditures [13][16]. Future Outlook for Commercial Insurance - The article anticipates a golden development period for commercial insurance as it becomes a vital supplementary payment method to meet the growing demand for high-quality medical services [3][21]. - By 2035, a comprehensive and sustainable multi-tiered healthcare system is expected to emerge, with commercial insurance playing a key role in financing and innovation within the healthcare sector [3][24]. Integration of Commercial Insurance - The integration of commercial insurance into the healthcare payment system is being accelerated through initiatives like one-stop settlement processes, which aim to simplify claims and enhance the role of commercial insurance in hospitals [21][23]. - The introduction of a commercial insurance drug list is expected to facilitate reasonable pricing for innovative drugs, thereby supporting pharmaceutical companies and enhancing the overall healthcare ecosystem [24][30]. Comparative Analysis with Developed Countries - The article draws comparisons with developed countries, noting that the U.S. healthcare system, which is primarily driven by commercial insurance, has established a market-oriented pricing mechanism that incentivizes innovation [28][30]. - In contrast, the UK's National Health Service (NHS) model, while providing universal coverage, has faced challenges in service delivery, leading to increased demand for commercial insurance as a supplementary option [31][32]. Conclusion - The article concludes that the evolution of commercial insurance in China is essential for creating a robust healthcare financing system that can adapt to the changing demographics and healthcare needs of the population [3][24].